Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) had 1-year ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

EW's first-quarter 2025 performance is likely to have gained from growth drivers across its businesses amid macroeconomic headwinds.

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.

At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement and surgery in patients at low surgical risk. Both groups had improvements in ...